Biomx Inc
PHGE1.960USD
-0.040-2.00%
交易中 （美东）报价延迟15分钟
2.76M总市值
亏损市盈率 TTM
关于 Biomx Inc 公司
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
Biomx Inc简介
公司代码PHGE
公司名称Biomx Inc
上市日期Dec 18, 2018
CEOSolomon (Jonathan Eitan)
员工数量52
证券类型Ordinary Share
年结日Dec 18
公司地址22 Einstein St.
城市NESS-ZIONA
上市交易所NASDAQ OMX – NASDAQ Basic Amex
国家Israel
邮编7414003
电话972723942377
网址https://www.biomx.com/
公司代码PHGE
上市日期Dec 18, 2018
CEOSolomon (Jonathan Eitan)
Biomx Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Jonathan Eitan Solomon
Mr. Jonathan Eitan Solomon
Chief Executive Officer, Director
Chief Executive Officer, Director
9.46K
--
Dr. Merav Bassan, Ph.D.
Dr. Merav Bassan, Ph.D.
Chief Development Officer
Chief Development Officer
5.86K
--
Ms. Marina Wolfson, CPA
Ms. Marina Wolfson, CPA
Chief Financial Officer
Chief Financial Officer
3.63K
-0.03%
Ms. Susan Blum, CPA
Ms. Susan Blum, CPA
Independent Director
Independent Director
--
--
Mr. Jonathan S. Leff
Mr. Jonathan S. Leff
Independent Director
Independent Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Jesse Goodman, M.D.
Dr. Jesse Goodman, M.D.
Independent Director
Independent Director
--
--
Dr. Russell G. Greig, Ph.D.
Dr. Russell G. Greig, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Eddie Williams
Mr. Eddie Williams
Independent Director
Independent Director
--
--
Mr. Gregory Merril
Mr. Gregory Merril
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Jonathan Eitan Solomon
Mr. Jonathan Eitan Solomon
Chief Executive Officer, Director
Chief Executive Officer, Director
9.46K
--
Dr. Merav Bassan, Ph.D.
Dr. Merav Bassan, Ph.D.
Chief Development Officer
Chief Development Officer
5.86K
--
Ms. Marina Wolfson, CPA
Ms. Marina Wolfson, CPA
Chief Financial Officer
Chief Financial Officer
3.63K
-0.03%
Ms. Susan Blum, CPA
Ms. Susan Blum, CPA
Independent Director
Independent Director
--
--
Mr. Jonathan S. Leff
Mr. Jonathan S. Leff
Independent Director
Independent Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月18日 周二
更新时间: 11月18日 周二
持股股东
股东类型
持股股东
持股股东
占比
Deerfield Management Company, L.P.
8.60%
Cystic Fibrosis Foundation
8.60%
Nantahala Capital Management, LLC
8.60%
Alyeska Investment Group, L.P.
5.48%
Centaurus Investments Limited
3.69%
其他
65.03%
持股股东
持股股东
占比
Deerfield Management Company, L.P.
8.60%
Cystic Fibrosis Foundation
8.60%
Nantahala Capital Management, LLC
8.60%
Alyeska Investment Group, L.P.
5.48%
Centaurus Investments Limited
3.69%
其他
65.03%
股东类型
持股股东
占比
Hedge Fund
26.70%
Corporation
12.29%
Holding Company
3.69%
Venture Capital
3.36%
Research Firm
1.49%
Individual Investor
1.33%
Investment Advisor/Hedge Fund
0.36%
Investment Advisor
0.09%
其他
50.69%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
38
10.55M
39.72%
-5.15M
2025Q2
48
19.36M
73.97%
+6.20M
2025Q1
47
17.95M
68.92%
+5.32M
2024Q4
47
13.90M
76.65%
+2.77M
2024Q3
43
13.00M
74.85%
+8.58M
2024Q2
33
4.45M
66.70%
+1.05M
2024Q1
34
2.97M
56.90%
+586.97K
2023Q4
35
2.25M
51.72%
+502.58K
2023Q3
39
1.91M
46.61%
-56.19K
2023Q2
39
1.94M
47.21%
+273.60K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Deerfield Management Company, L.P.
2.49M
9.39%
--
--
Jun 30, 2025
Cystic Fibrosis Foundation
2.49M
9.39%
+706.35K
+39.51%
Feb 27, 2025
Nantahala Capital Management, LLC
2.49M
9.39%
--
--
Jun 30, 2025
Centaurus Investments Limited
1.07M
4.03%
+1.07M
--
Apr 21, 2025
AMR Action Fund LP
876.89K
3.3%
+571.40K
+187.05%
Sep 30, 2024
Telmina Ltd
560.27K
2.11%
+276.30K
+97.30%
Sep 30, 2024
Nimble Ventures LLC
510.20K
1.92%
+1.00
+0.00%
Sep 30, 2024
J.P. Morgan Securities LLC
430.00K
1.62%
--
--
Jun 30, 2025
Dafna Capital Management, LLC
401.14K
1.51%
--
--
Jun 30, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
公告日期
类型
比率
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
常见问题
Biomx Inc的前五大股东是谁？
Biomx Inc 的前五大股东如下：
Deerfield Management Company, L.P.持有股份：2.49M，占总股份比例：9.39%。
Cystic Fibrosis Foundation持有股份：2.49M，占总股份比例：9.39%。
Nantahala Capital Management, LLC持有股份：2.49M，占总股份比例：9.39%。
Centaurus Investments Limited持有股份：1.07M，占总股份比例：4.03%。
AMR Action Fund LP持有股份：876.89K，占总股份比例：3.30%。
Deerfield Management Company, L.P.持有股份：2.49M，占总股份比例：9.39%。
Cystic Fibrosis Foundation持有股份：2.49M，占总股份比例：9.39%。
Nantahala Capital Management, LLC持有股份：2.49M，占总股份比例：9.39%。
Centaurus Investments Limited持有股份：1.07M，占总股份比例：4.03%。
AMR Action Fund LP持有股份：876.89K，占总股份比例：3.30%。
Biomx Inc的前三大股东类型是什么？
Biomx Inc 的前三大股东类型分别是：
Deerfield Management Company, L.P.
Cystic Fibrosis Foundation
Nantahala Capital Management, LLC
Deerfield Management Company, L.P.
Cystic Fibrosis Foundation
Nantahala Capital Management, LLC
有多少机构持有Biomx Inc(PHGE)的股份？
截至2025Q3，共有38家机构持有Biomx Inc的股份，合计持有的股份价值约为10.55M，占公司总股份的39.72%。与2025Q2相比，机构持股有所增加，增幅为-34.24%。
哪个业务部门对Biomx Inc的收入贡献最大？
在--，--业务部门对Biomx Inc的收入贡献最大，创收--，占总收入的--%。
